Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis

PLoS One. 2012;7(8):e42704. doi: 10.1371/journal.pone.0042704. Epub 2012 Aug 3.

Abstract

Promoter methylation profiles are proposed as potential prognosis and/or diagnosis biomarkers in cervical cancer. Up to now, little is known about the promoter methylation profile and expression pattern of stem cell (SC) markers during tumor development. In this study, we were interested to identify SC genes methylation profiles during cervical carcinogenesis. A genome-wide promoter methylation screening revealed a strong hypermethylation of Undifferentiated cell Transcription Factor 1 (UTF1) promoter in cervical cancer in comparison with normal ectocervix. By direct bisulfite pyrosequencing of DNA isolated from liquid-based cytological samples, we showed that UTF1 promoter methylation increases with lesion severity, the highest level of methylation being found in carcinoma. This hypermethylation was associated with increased UTF1 mRNA and protein expression. By using quantitative RT-PCR and Western Blot, we showed that both UTF1 mRNA and protein are present in epithelial cancer cell lines, even in the absence of its two main described regulators Oct4A and Sox2. Moreover, by immunofluorescence, we confirmed the nuclear localisation of UTF1 in cell lines. Surprisingly, direct bisulfite pyrosequencing revealed that the inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine was associated with decreased UTF1 gene methylation and expression in two cervical cancer cell lines of the four tested. These findings strongly suggest that UTF1 promoter methylation profile might be a useful biomarker for cervical cancer diagnosis and raise the questions of its role during epithelial carcinogenesis and of the mechanisms regulating its expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / pharmacology
  • Carcinoma, Ovarian Epithelial
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cell Transformation, Neoplastic / genetics*
  • Cell Transformation, Neoplastic / pathology
  • Cervix Uteri / drug effects
  • Cervix Uteri / metabolism
  • Cervix Uteri / pathology
  • Cluster Analysis
  • Cytological Techniques
  • DNA Methylation / drug effects
  • DNA Methylation / genetics*
  • DNA, Neoplasm / isolation & purification
  • Female
  • Gene Expression Regulation, Neoplastic* / drug effects
  • Genes, Neoplasm / genetics
  • Humans
  • Neoplasms, Glandular and Epithelial / genetics
  • Neoplasms, Glandular and Epithelial / pathology
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism
  • Neoplastic Stem Cells / pathology
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / metabolism
  • Octamer Transcription Factor-3 / genetics
  • Octamer Transcription Factor-3 / metabolism
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology
  • Promoter Regions, Genetic*
  • SOXB1 Transcription Factors / genetics
  • SOXB1 Transcription Factors / metabolism
  • Sequence Analysis, DNA
  • Trans-Activators / genetics*
  • Trans-Activators / metabolism
  • Uterine Cervical Neoplasms / genetics*
  • Uterine Cervical Neoplasms / pathology

Substances

  • DNA, Neoplasm
  • Nuclear Proteins
  • Octamer Transcription Factor-3
  • POU5F1 protein, human
  • SOX2 protein, human
  • SOXB1 Transcription Factors
  • Trans-Activators
  • UTF1 protein, human
  • Azacitidine

Grants and funding

This work was supported by the Program of the Walloon Region (Neoangio N° 616476) and the Belgian Fund for Medical Scientific Research (FNRS). Samuel Guenin and Xavier Lampe are supported by Neoangio. Mustapha Mouallif is supported by a grant from the Averroes Program of the European Commission and by a Télévie grant from the F.R.S-FNRS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.